Evidence map›Paper›PMID 20630463›Full record

Trial reportJACC. Cardiovascular interventions2010

Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study.

Giulio Guagliumi, Vasile Sirbu, Hiram Bezerra, Giuseppe Biondi-Zoccai, Luigi Fiocca, Giuseppe Musumeci, Aleksandre Matiashvili, Nikoloz Lortkipanidze, Satoko Tahara, Orazio Valsecchi and 1 more

3 registry-linked trialsAbstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in JACC. Cardiovascular interventions, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02621489 phase4completedstarted 2015, after this paper: background citation

Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects

Ran2015Enrolled38Registered outcomes16Posted comparisons0ConditionsAtherosclerosis, Diabetes, RestenosisArmsBydureon, Humulin kwickpen, Metformin
Open the trial in the graph
NCT00704561 nacompletednot on this map

Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).

TypeinterventionalSponsorA.O. Ospedale Papa Giovanni XXIIIRan2008 to 2009Enrolled44ConditionsAcute Myocardial InfarctionArmsENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA), DRIVER bare metal stent (Medtronic, Santa Rosa, Ca), Coronary stent implantation, Bare Metal Coronary Stent
NCT01239654 phase3completednot on this map

Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study

TypeinterventionalSponsorIRCCS San RaffaeleRan2010 to 2011Enrolled60ConditionsAcute Coronary SyndromeArmsstent implantation
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Drug-eluting stents versus bare-metal stents for acute coronary syndrome.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. The use of drug-eluting stents in acute myocardial infarction - is the battle coming to an end? From despair to acceptance.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2013
    Review
  14. Contemporary assessment of stent strut coverage by OCT.The international journal of cardiovascular imaging · 2013
    Article
  15. Article
  16. Article
  17. Article
  18. Optical Coherence Tomography: Potential Clinical Applications.Current cardiovascular imaging reports · 2012
    Article
  19. Optical coherence tomography: from research to practice.European heart journal. Cardiovascular Imaging · 2012
    Review
  20. Optical coherence tomography endpoints in stent clinical investigations: strut coverage.The international journal of cardiovascular imaging · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Giulio GuagliumiDivision of Cardiology, Cardiovascular Department, Ospedali Riuniti, Bergamo, Italy. guagliumig@gmail.com
Vasile Sirbu
Hiram Bezerra
Giuseppe Biondi-Zoccai
Luigi Fiocca
Giuseppe Musumeci
Aleksandre Matiashvili
Nikoloz Lortkipanidze
Satoko Tahara
Orazio Valsecchi
Marco Costa
Azienda Ospedaliero Universitaria Ospedali Riuniti · ITUniversity Hospitals Cleveland Medical Center · USUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesUsing optical coherence tomography, we assessed the proportion of uncovered struts at 6-month follow-up in zotarolimus-eluting stents (ZES), specifically Endeavor (Medtronic CardioVascular, Santa Rosa, California) stents, and identical bare-metal stents (BMS) implanted in patients with ST-segment elevation myocardial infarction (STEMI).

backgroundSirolimus- and paclitaxel-eluting stents implanted in STEMI have been associated with delayed healing and incomplete strut coverage. ZES are associated with a more complete and uniform strut coverage in stable patients, but whether this holds true also after STEMI is unknown.

methodsForty-four patients with STEMI who underwent primary PCI were randomized to ZES or BMS (3:1 randomization). Angiographic, intravascular ultrasound, and optical coherence tomography follow-up was conducted at 6 months and clinical follow-up at 1 year. All images were analyzed by an independent core laboratory that was blind to stent assignments.

resultsThere were no differences between ZES and BMS in percentage of uncovered struts (median: 0.00% [interquartile range (IQR): 0.00% to 1.78%] vs. 1.98% [IQR: 0.21% to 7.33%], p = 0.13), maximum length of uncovered segments (0.00 [IQR: 0.00 to 1.19] mm vs. 1.38 [IQR: 0.65 to 3.30] mm, p = 0.10), percentage of malapposed struts (0.00% [IQR: 0.00% to 0.23%] vs. 0.15% [IQR: 0.00% to 5.81%], p = 0.16), and maximum length of malapposed segments (0.00 [IQR: 0.00 to 0.67] mm vs. 0.33 [IQR: 0.00 to 2.55] mm, p = 0.20). Neointimal response was similar between ZES and BMS (332 [IQR: 240 to 429] microm vs. 186 [IQR: 136 to 348] microm, p = 0.99) and evenly distributed. No late acquired malapposition was observed in both groups. There were no deaths, myocardial infarction, or stent thromboses at 1 year.

conclusionsThis optical coherence tomography study found no difference in strut coverage and similar vessel response to ZES, when compared with identical BMS, implanted during primary percutaneous coronary intervention in STEMI patients. (Six-Month Coverage and Vessel Wall Response of the Zotarolimus Drug-Eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography [OCTAMI]; NCT00704561).

Indexed as

Drug-Eluting StentsMetalsStentsTomography, Optical CoherenceAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary VesselsFemaleHumansMaleMiddle AgedMyocardial InfarctionPredictive Value of TestsProspective StudiesCardiovascular AgentsMetalsSirolimuszotarolimus

Identifiers

PMID20630463
OpenAlexW90137233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.